Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
PRFX
PRFX | US
2.20
USD-0.08
-3.51%
PRFX | US
About PRFX
Sector
Healthcare
Industry
Drug Manufacturers-Specialty & Generic
Earnings date
30/06/2024
As of date
24/03/2026
Close
2.20
Open
2.23
High
2.25
Low
2.16
PainReform Ltd. a clinical stage specialty pharmaceutical company engages in the development of therapeutics that provides an extended period of post-surgical pain relief in Israel. The company engages in developing PRF-110 a viscous clear oil-based solution that is instilled directly into the surgical wound to provide localized and extended post-operative analgesia. It is currently conducting Phase 3 clinical trials of PRF-110 for the treatment of patients undergoing bunionectomy surgery and hernia repair. The company was incorporated in 2007 and is based in Tel Aviv Israel.
View LessPRFX | US
Risk
74.5
Sharpe
-0.73
Luna's Score
43/100
Recommendation
Sell
Luna says (PRFX | US)
What's Working
Low Market Beta (-0.4 to 0.8)
Low Debt to Equity (< 0.25)
Value Stock (Price to Book < 3)
What's not Working
Negative Momentum (Declining Price)
Price Below SMA10D
High 6-Month Volatility (>65%)
Microcap (<300M USD)
Weak Sharpe Ratio (< 0.3)
Volatility Signals
Bearish: Increased Volatility (6-month > 1-month volatility)
Risk Meter
10 days
64.8%1 month
74.5%3 months
121.1%6 months
101.4%Returns
Fundamental Ratios
PE
-
Fwd. PE
-
Price to book
0.63
Debt to equity
-0.03
Debt to assets
0.02
Ent. to EBITDA
-2.32
Ent. to rev.
-
PEG
-
Other Fundamentals
EBITDA
-17.81M
MarketCap
4.90M
MarketCap(USD)
4.90M
Div. yield
-
Op. margin
-
Erngs. growth
-
Rev. growth
-
Ret. on equity
-716.67
Short ratio
0.07
Short perc.
2.65
Market Sentiment (SMA and Price signals)
Short-term: Bearish (SMA10D < SMA1M)
Intermediate-term: Bearish (SMA1M < SMA3M)
Long-term: Bearish (SMA6M < SMA12M)
SMAs: Stock Price Trends
Range10D
0.87
Range1M
1.36
Range3M
3.13
Volumes: Market Activity
Rel. volume
0.52
Price X volume
36.30K
Peers
Diversifiers
Industry Comparison
| Parameter | Company | Industry | Indicator |
|---|---|---|---|
| Enterprise to EBITDA | -2.32 | - | Cheaper |
| Ent. to Revenue | - | - | - |
| PE Ratio | - | 30.05 | - |
| Price to Book | 0.63 | 13.15 | Cheaper |
| Dividend Yield | - | - | - |
| Std. Deviation (3M) | 121.07 | - | Riskier |
| Debt to Equity | -0.03 | -1.88 | Expensive |
| Debt to Assets | 0.02 | 0.48 | Cheaper |
| Market Cap | 4.90M | - | Emerging |
